Clinical Trial Update: Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating pharmacokinetic guided dose escalation and confirmation using oral decitabine with the oral cytidine deaminase inhibitor cedazuridine…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Cedazuridine (Cedazuridine)
• Decitabine (Decitabine)

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Myelodysplastic Syndrome, MDS | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-10-19